Surging Prevalence Of Hereditary Angioedema Ignites Growth In The Market: A Key Factor Shaping the Future of the Hereditary Angioedema Therapeutics Market in 2025

"How Are the key drivers contributing to the expansion of the hereditary angioedema therapeutics market?
The hereditary angioedema market is expected to expand due to the increasing occurrence of the disease. Hereditary angioedema (HAE) is an uncommon genetic condition marked by recurring cases of severe swelling in the skin and mucus membranes, caused by the accumulation of excess fluid, or edema. This swelling can happen anywhere in the body, such as in the hands, feet, face, intestines, and airways. For example, in June 2022, Rare Disease Advisor, a digital health resource for professionals worldwide, reported that hereditary angioedema affects one in every 50,000 individuals, with prevalence rates varying from 1:10,000 to 1:150,000. HAE episodes prompt between 15,000 and 30,000 visits to the emergency department in the US annually. Around 5.8% of HAE cases reported an average diagnosis time of 0 to 6 months, while the same percentage had an average diagnosis time of over a decade. Thus, the increasing incidence of hereditary angioedema is contributing to the growth of the hereditary angioedema market.

Get Your Hereditary Angioedema Therapeutics Market Report Here:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

What growth opportunities are expected to drive the hereditary angioedema therapeutics market's CAGR through 2034?
The market size for therapeutics in hereditary angioedema has seen a swift expansion in recent times. The industry is projected to rise from a worth of $6.68 billion in 2024 to an estimated value of $7.84 billion in 2025, displaying a compound annual growth rate (CAGR) of 17.3%. The earlier growth trends noticed can be credited to enhanced diagnosis and awareness, broadening treatment accessibility, advancements in research and development, patient empowerment and education, in addition to regulatory authorizations.

Rapid expansion is projected in the hereditary angioedema therapeutics market over the coming years, with a growth forecast to reach $16.11 billion by 2029, representing a compound annual growth rate (CAGR) of 19.7%. This predicted growth during the forecast period can be associated with progress in targeted therapies, the expansion of the global market, advances in gene therapy, the trend towards personalized medicine, and collaborations in research and treatment. Key trends expected during this forecast period include global access initiatives, research into health economic outcomes, strategies for early intervention, and therapeutic approaches to pediatric HAE.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What are the emerging trends shaping the future of the hereditary angioedema therapeutics market?
The rise in product innovation is a significant trend observed in the hereditary angioedema therapeutics market. Key players in the market are focusing on developing novel medical solutions such as ligand-conjugated (LICA) investigational antisense medicine and gene therapy to maintain their market standing. For example, in March 2023, US-based clinical-stage biotechnology firm Intellia Therapeutics launched a new Investigational New Drug (IND), NTLA-2002, which received clearance from the United States Food and Drug Administration to be used for hereditary angioedema treatment. This approval allows the company to continue its global Phase 1/2 trial, including the United States in the Phase 2 segment. A single dose of this treatment can permanently decrease plasma kallikrein protein activity and ward off HAE attacks, thanks to the permanent inactivation of the target gene, KLKB1, or kallikrein B1. NTLA-2002 is a potential candidate for in vivo genome editing.

Which growth-oriented segments of the hereditary angioedema therapeutics market are leading the industry's development?
The hereditary angioedema therapeutics market covered in this report is segmented -

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand

Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10810

What regions are leading the charge in the hereditary angioedema therapeutics market?
North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What companies are at the forefront of innovation in the hereditary angioedema therapeutics market?
Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Is Covered In The Hereditary Angioedema Therapeutics Global Market Report?

• Market Size Forecast: Examine the hereditary angioedema therapeutics market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the hereditary angioedema therapeutics market for a structured understanding.
• Key Players Overview: Analyze major players in the hereditary angioedema therapeutics market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the hereditary angioedema therapeutics market.
• Segment Contributions: Evaluate how different segments drive overall growth in the hereditary angioedema therapeutics market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the hereditary angioedema therapeutics market.
• Industry Challenges: Identify potential risks and obstacles affecting the hereditary angioedema therapeutics market.
• Competitive Landscape: Review strategic developments in the hereditary angioedema therapeutics market, including expansions, agreements, and new product launches.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.